Optimisation of circulating biomarkers of cell death for routine clinical use

Annals of Oncology - Tập 19 - Trang 990-995 - 2008
A. Greystoke1,2, J. Cummings1, T. Ward1, K. Simpson1, A. Renehan3, F. Butt1, D. Moore1, J. Gietema4, F. Blackhall2,3, M. Ranson2,3, A. Hughes3,5, C. Dive1,3
1Department of Medical Oncology, Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, Manchester, UK
2Department of Medical Oncology, Christie Hospital Foundation Trust, Manchester, UK
3School of Cancer and Imaging Sciences, University of Manchester, Manchester, UK
4Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands
5Discovery Medicine, AstraZeneca Discovery Medicine, Alderley Park, Macclesfield, UK

Tài liệu tham khảo

Holdenrieder, 2001, Nucleosomes in serum of patients with benign and malignant diseases, Int J Cancer, 95, 114, 10.1002/1097-0215(20010320)95:2<114::AID-IJC1020>3.0.CO;2-Q

Roth, 2004, Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope m30 in critically ill patients, Shock, 22, 218, 10.1097/01.shk.0000136098.49672.0e

Gonzalez-Quintela, 2006, Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19, Alcohol, 38, 45, 10.1016/j.alcohol.2006.01.003

Adlbrecht, 2007, Elevated levels of interleukin-1beta-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction, Eur J Clin Invest, 37, 372, 10.1111/j.1365-2362.2007.01803.x

Cummings, 2006, Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP, Br J Cancer, 95, 42, 10.1038/sj.bjc.6603220

Cummings, 2005, Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP, Br J Cancer, 92, 532, 10.1038/sj.bjc.6602363

Holdenrieder, 2006, Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments, Ann N Y Acad Sci, 1075, 244, 10.1196/annals.1368.033

Pichon, 2006, Variations of soluble fas and cytokeratin 18-asp 396 neo-epitope in different cancers during chemotherapy, Anticancer Res, 26, 2387

Barczyk, 2005, Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy, Int J Cancer, 116, 167, 10.1002/ijc.21037

Neuber, 2006, Expression of fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival, Onkologie, 29, 361

Moll, 1982, The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells, Cell, 31, 11, 10.1016/0092-8674(82)90400-7

Galluzzi, 2007, Cell death modalities: classification and pathophysiological implications, Cell Death Differ, 14, 1237, 10.1038/sj.cdd.4402148

Kramer, 2006, Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles, Br J Cancer, 94, 1592, 10.1038/sj.bjc.6603129

Ueno, 2003, Measurement of an apoptotic product in the sera of breast cancer patients, Eur J Cancer, 39, 769, 10.1016/S0959-8049(02)00865-1

Ulukaya, 2007, The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival, Lung Cancer, 56, 399, 10.1016/j.lungcan.2007.01.015

Peviva, 2005

Webb, 1998, Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: Implications for measurement of circulating VEGF levels in clinical disease, Clin Sci (Lond), 94, 395, 10.1042/cs0940395

Hoffbrand, 2005, 1080

DRG Instruments, 2005, CYFRA 21-1 ELISA Instructions for Use (ed 2005-03-01), DRG Instruments

Evans, 2001, Effect of anticoagulants and storage temperature on stability of plasma and serum hormones, Clin Biochem, 34, 107, 10.1016/S0009-9120(01)00196-5

Seed, 2001, Comparing several methods of measuring the same quality, Stata Tech Bull, 10, 73

Cummings, 2007, Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma, Cancer Chemother Pharmacol, 60, 921, 10.1007/s00280-007-0437-4

Oloffson, 2007, Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy, Clin Cancer Res, 13

Hoffmann, 1994, Automated and semiautomated analysis of rat alkaline phosphatase isoenzymes, Toxicol Pathol, 22, 633, 10.1177/019262339402200607

Einarsson, 1999, Performance characteristics of IMMULITE TPS: A comparison with TPS IRMA, Anticancer Res, 19, 2743

Sarwar, 1994, CYFRA 21-1 as a tumor marker used in measuring the serum fragment of cytokeratin subunit 19 by immunoradiometric assay, Ann Nucl Med, 8, 301, 10.1007/BF03165035

Peviva: M30-Apoptosense ELISA Instructions for Use (ed 2007-01-29), Peviva 2007

Thông tin
Thông tin xuất bản

Annals of Oncology

Tập 19

990-995

Thông tin tác giả